

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED
康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 867)

Inside Information and Business Update Announcement
Supplemental Information in relation to the Release of Top Line Data of Phase
III INTEREST Trial for Traumakine®

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the earlier announcement of China Medical System Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 8 May 2018 (the “**Announcement**”) in relation to the announcement of Faron Pharmaceuticals, Ltd regarding the top line data from its pan-European Phase III INTEREST trial with the product Traumakine® (the “**Product**”). As disclosed in the Announcement, the INTEREST study in Europe did not meet the Day 28 (D28) primary efficacy composite endpoint of ventilator free days and survival with Traumakine® treatment.

The Company believes that, under the current circumstances, the Product will not be able to obtain the necessary regulatory approval for it to be marketed based on the above results. While the results of the clinical trial are disappointing, the directors of the Company do not believe that they have any material impact on the financial results of the Group.

Shareholders and investors are advised to exercise caution in dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 8 May 2018

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive directors; and (ii) Mr. Cheung Kam Shing, Terry, Mr. Wu Chi Keung and Mr. Leung Chong Shun as independent non-executive directors.